Browsing by Author "Karabulut, Bülent"

Now showing 1 - 3 of 3

A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer
(Imprimatur Publications, 2013) Karabulut, Bülent; Özdemir, Feyyaz; Tunalı, Didem; Kurt, Ender; Çubukçu, Erdem; Ölmez, Ömer Fatih; Kurt, Meral; Avcı, Nilüfer; Evrensel, Türkkan; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Veterinerlik Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; 0000-0003-1637-910X; 0000-0002-9732-5340; AAJ-1027-2021; AAA-3961-2020; 7006207332; 53986153800; 26435400000; 8843050600; 55390409800; 6603942124; 6602587152
Purpose: Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC). Methods: Patients with AGC who were >= 65 years old and were treated with carboplatin (area under the curve/AUG 5, on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed. Results: A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11(36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 +/- 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 +/- 1.0 months (95% CI: 9.2-12.1). Conclusion: Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
(BMC, 2020-03-30) Yalçın, Şuayıb; Dane, Faysal; Öksüzoğlu, Berna; Özdemir, Nuriye Yıldırım; Özkan, Metin; Demirağ, Güzin Gönüllü; Coşkun, Hasan Şenol; Karabulut, Bülent; Ustaoglu, Mehmet Ali; Özdemir, Feyyaz; Turna, Hande; Yavuzşen, Tuğba; Aykan, Faruk; Sevinç, Alper; Akbulut, Hakan; Yüce, Deniz; Hayran, Mutlu; Kılıçkap, Saadettin; Evrensel, Türkkan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
BackgroundCombination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown.MethodsA total of 125 patients were randomized to combination therapy (1000mg/m2 gemcitabine +125mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000mg/m2) arms to take treatment weekly for 7 of 8weeks, and following 3 of 4weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL.ResultsOverall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p=0.018). These proportions were 27.3 and 36.6% in 6(th) month assessments, respectively (p=0.357). Median overall survivals in combination and single-agent arms were 9.92months and 5.95months, respectively (HR: 0.64, 95% CI: 0.42-0.86, p=0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22months, respectively (HR: 0.58, 95% CI: 0.39-0.87, p=0.008). Median time-to-deterioration were 5.36 vs 3.68months, and objective response rates were 37.1% vs 23.7% (p=0.009), respectively in combination and single-agent arms.ConclusionsCombination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer.Trial registrationThis study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).
Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma
(Wiley, 2005-05) Sezgin, Canfeza; Veral, Ali; Karabulut, Bülent; Göker, Erdem; Kurt, Ender; Evrensel, Türkkan; Yalçınkaya, Ülviye; Kanat, Özkan; Demiray, Mutlu; Arslan, Murat; Ercan, İlker; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-2382-290X; 0000-0003-2501-3097; 0000-0002-9732-5340; M-8060-2019; AAJ-1027-2021; 7006207332; 6603942124; 6508300295; 55881548500; 6603631569; 57197925370; 6603789069; 6602587152
In this study, we aimed to investigate the clinicopathological characteristics with special emphasis on c-kit expression and the treatment results of patients with extrapulmonary small cell carcinoma (EPSCC). The medical records of the patients with EPSCC were reviewed, and the data regarding patient and tumour characteristics, treatment and clinical outcome were retrieved and analysed. A total of 28 patients with the diagnosis of EPSCC were identified. There were 19 males and 9 females, with a mean age of 56.5 years. Patients with limited disease (LD) (n = 13) were treated with surgery, chemotherapy (CT) and radiotherapy with different sequences. Patients with extensive disease (ED) (n = 15) were mainly treated with combination CT. The median overall survival was 14.5 months in patients with LD compared to 11 months in those with ED (p = 0.029). Ten patients (36%) showed c-kit overexpression. There was no significant difference between the survival of c-kit-positive and c-kit-negative patients (p = 0.367). In conclusion, our study demonstrates that the prognosis of EPSCC is poor despite currently available treatments. C-kit may be considered as a potential target for novel therapeutical approaches.